These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33675901)

  • 1. ADAM10: Biomarker of mild cognitive impairment but not of cognitive frailty.
    Vatanabe IP; Pedroso RV; Manzine PR; Chagas MHN; de Morais Fabrício D; Grigoli MM; Naves MA; Pott-Jr H; Cominetti MR
    Exp Gerontol; 2021 Jul; 149():111303. PubMed ID: 33675901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study.
    Oliveira Monteiro MPA; Salheb Oliveira DSM; Manzine PR; Crispim Nascimento CM; Dos Santos Orlandi AA; de Oliveira Gomes GA; Dos Santos Orlandi F; Zazzetta MS; Pott-Junior H; Cominetti MR
    Alzheimers Res Ther; 2021 Jan; 13(1):18. PubMed ID: 33419480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma ADAM10 Levels and Their Association with Alzheimer's Disease Diagnosis in Older Adults with Fewer Years of Formal Education.
    Pelegrini LNC; da Silva VA; Grigoli MM; Vatanabe IP; Manzine PR; Cominetti MR
    Dement Geriatr Cogn Disord; 2024; 53(3):153-161. PubMed ID: 38583419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADAM10 gene expression in the blood cells of Alzheimer's disease patients and mild cognitive impairment subjects.
    Manzine PR; Marcello E; Borroni B; Kamphuis W; Hol E; Padovani A; Nascimento CC; de Godoy Bueno P; Assis Carvalho Vale F; Iost Pavarini SC; Di Luca M; Cominetti MR
    Biomarkers; 2015; 20(3):196-201. PubMed ID: 26220620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADAM10 Plasma and CSF Levels Are Increased in Mild Alzheimer's Disease.
    Pereira Vatanabe I; Peron R; Mantellatto Grigoli M; Pelucchi S; De Cesare G; Magalhães T; Manzine PR; Figueredo Balthazar ML; Di Luca M; Marcello E; Cominetti MR
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33670873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrochemical magneto-immunoassay for detection of ADAM10 Alzheimer's biomarker using gold nanoparticles as label.
    de Oliveira TR; Manzine PR; Cominetti MR; Leite OD; Faria RC
    Talanta; 2024 Jan; 266(Pt 2):125042. PubMed ID: 37591151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer's disease patients.
    Bram JMF; Talib LL; Joaquim HPG; Sarno TA; Gattaz WF; Forlenza OV
    Eur Arch Psychiatry Clin Neurosci; 2019 Dec; 269(8):963-972. PubMed ID: 29845446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADAM10 as a biomarker for Alzheimer's disease: A systematic review.
    Oliveira Monteiro E Pereira de Almeida MP; Valle Pedroso R; Mantellatto Grigoli M; Vicente Silva T; Manzine PR; Cominetti MR
    Rev Neurol (Paris); 2024; 180(1-2):1-11. PubMed ID: 37460331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment.
    Shen Y; Wang H; Sun Q; Yao H; Keegan AP; Mullan M; Wilson J; Lista S; Leyhe T; Laske C; Rujescu D; Levey A; Wallin A; Blennow K; Li R; Hampel H
    Biol Psychiatry; 2018 Mar; 83(5):447-455. PubMed ID: 28359566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet Membrane β-Secretase Activity in Mild Cognitive Impairment and Conversion to Dementia: a Longitudinal Study.
    McGuinness B; Fuchs M; Barrett SL; Passmore AP; Johnston JA
    J Alzheimers Dis; 2016; 49(4):1095-103. PubMed ID: 26639974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADAM10 as a biomarker for Alzheimer's disease: a study with Brazilian elderly.
    Manzine PR; de França Bram JM; Barham EJ; do Vale Fde A; Selistre-de-Araújo HS; Cominetti MR; Iost Pavarini SC
    Dement Geriatr Cogn Disord; 2013; 35(1-2):58-66. PubMed ID: 23306532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Case for Stage-Specific Frailty Interventions Spanning Community Aging to Cognitive Impairment.
    Chong MS; Tay L; Ismail NH; Tan CH; Yew S; Yeo A; Ye R; Leung B; Ding YY
    J Am Med Dir Assoc; 2015 Nov; 16(11):1003.e13-9. PubMed ID: 26543008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging biomarkers and screening for cognitive frailty.
    Ruan Q; D'Onofrio G; Sancarlo D; Greco A; Lozupone M; Seripa D; Panza F; Yu Z
    Aging Clin Exp Res; 2017 Dec; 29(6):1075-1086. PubMed ID: 28260159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Cognitive Frailty: Clinical and Neurobiological Roadmap for a Single Complex Phenotype.
    Panza F; Seripa D; Solfrizzi V; Tortelli R; Greco A; Pilotto A; Logroscino G
    J Alzheimers Dis; 2015; 47(4):793-813. PubMed ID: 26401761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olfactory function and neuropsychological profile to differentiate dementia with Lewy bodies from Alzheimer's disease in patients with mild cognitive impairment: A 5-year follow-up study.
    Yoon JH; Kim M; Moon SY; Yong SW; Hong JM
    J Neurol Sci; 2015 Aug; 355(1-2):174-9. PubMed ID: 26076880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Accuracy of Digital Biomarker Technologies for Detection of Mild Cognitive Impairment and Pre-Frailty Amongst Older Adults: A Systematic Review and Meta-Analysis.
    Teh SK; Rawtaer I; Tan HP
    IEEE J Biomed Health Inform; 2022 Aug; 26(8):3638-3648. PubMed ID: 35737623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging.
    Solfrizzi V; Scafato E; Lozupone M; Seripa D; Giannini M; Sardone R; Bonfiglio C; Abbrescia DI; Galluzzo L; Gandin C; Baldereschi M; Di Carlo A; Inzitari D; Daniele A; Sabbà C; Logroscino G; Panza F;
    Am J Geriatr Psychiatry; 2017 Nov; 25(11):1236-1248. PubMed ID: 28689645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.